摘要2025年5月30日，世界卫生组织发布了《关于婴儿呼吸道合胞病毒免疫接种立场文件（2025版）》（以下简称立场文件）。世界卫生组织建议，各国应使用呼吸道合胞病毒（RSV）疫苗或长效单克隆抗体等产品预防因RSV感染引起的重症疾病，并针对免疫程序和接种计划、安全性及禁忌证、免疫制剂的选择、现有卫生体系的整合、监测、特殊人群疫苗接种以及未来需要开展的优先研究领域给予了相应指导建议。本文分析了此立场文件对我国RSV免疫接种的启示：（1）扩大已获批RSV单抗的应用；（2）加速免疫制品研发与引入；（3）明确接种策略与实施路径；（4）完善配套的监测与评估工作；（5）加强专业人员培训与公众教育；（6）优化部门间协同合作。

abstractsOn May 30, 2025, World Health Organization (WHO) position paper on immunization to protect infants against respiratory syncytial virus (RSV) disease, May 2025 was published (hereinafter referred to as the position paper). The WHO recommends that countries use RSV vaccines or long-acting monoclonal antibodies to prevent severe RSV-related diseases. It provides guidance on immunization schedules and timing, safety and contraindications, product choice, health system integration, surveillance, vaccination of special-population, and research priorities. This paper analyzes the position paper′s implications for RSV immunization in China: (1) expanding the application of approved monoclonal antibodies; (2) speeding up the research, development, and introduction of immune products; (3) clarifying vaccination strategies and implementation paths; (4) improving monitoring and evaluation;(5) strengthening professional training and public education; (6) optimizing inter-departmental cooperation.